Jeffrey Krischer

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. pmc The use of intermediate endpoints in the design of type 1 diabetes prevention trials
    Jeffrey P Krischer
    Division of Informatics and Biostatistics, Department of Pediatrics, University of South Florida, Tampa, FL 33612, USA
    Diabetologia 56:1919-24. 2013
  2. pmc Safety of purified isoflavones in men with clinically localized prostate cancer
    Nagi B Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Nutr Cancer 59:169-75. 2007
  3. pmc A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer
    Nagi B Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Nutr Cancer 59:163-8. 2007
  4. ncbi request reprint Role of insulin resistance in predicting progression to type 1 diabetes
    Ping Xu
    Pediatrics Epidemiology Center, University of South Florida, Tampa, Florida 33612, USA
    Diabetes Care 30:2314-20. 2007
  5. pmc Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research
    Rachel L Richesson
    Pediatrics Epidemiology Center, University of South Florida College of Medicine, Department of Pediatrics, Tampa, FL 33612, USA
    J Am Med Inform Assoc 13:536-46. 2006
  6. ncbi request reprint Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes
    Jeffrey P Krischer
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612 9497, USA
    J Clin Endocrinol Metab 88:103-8. 2003
  7. ncbi request reprint Lysophospholipids are potential biomarkers of ovarian cancer
    Rebecca Sutphen
    Department of Interdisciplinary Oncology, College of Medicine and H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, 33612, USA
    Cancer Epidemiol Biomarkers Prev 13:1185-91. 2004
  8. pmc A randomized controlled trial to increase cancer screening among attendees of community health centers
    Richard G Roetzheim
    Department of Family Medicine, University of South Florida, Tampa, Fla 33612, USA
    Ann Fam Med 2:294-300. 2004
  9. ncbi request reprint Colorectal cancer screening among a sample of community health center attendees
    Lisa K Christman
    Fuller Theological Seminary, USA
    J Health Care Poor Underserved 15:281-93. 2004
  10. ncbi request reprint Male sex increases the risk of autoimmunity but not type 1 diabetes
    Jeffrey P Krischer
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Diabetes Care 27:1985-90. 2004

Research Grants

  1. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2003
  2. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2007
  3. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2007
  4. Trial to Reduce IDDM in the Genetically at Risk (TRIGR) Data Management Unit
    Jeffrey Krischer; Fiscal Year: 2007
  5. DATA COORDINATING CENTER
    Jeffrey Krischer; Fiscal Year: 2006
  6. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2006
  7. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2005
  8. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2004
  9. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2005
  10. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2004

Collaborators

Detail Information

Publications21

  1. pmc The use of intermediate endpoints in the design of type 1 diabetes prevention trials
    Jeffrey P Krischer
    Division of Informatics and Biostatistics, Department of Pediatrics, University of South Florida, Tampa, FL 33612, USA
    Diabetologia 56:1919-24. 2013
    ..This paper presents a rationale for the selection of intermediate endpoints to be used in the design of type 1 diabetes prevention clinical trials...
  2. pmc Safety of purified isoflavones in men with clinically localized prostate cancer
    Nagi B Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Nutr Cancer 59:169-75. 2007
    ..With the current evidence on the cancer preventive properties of isoflavones, these results are significant and offer promise for these phytochemicals to be developed as potent agents to prevent cancer progression...
  3. pmc A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer
    Nagi B Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Nutr Cancer 59:163-8. 2007
    ..The study establishes the need to explore other potential mechanisms by which prolonged and consistent purified isoflavone consumption may modulate prostate cancer risk...
  4. ncbi request reprint Role of insulin resistance in predicting progression to type 1 diabetes
    Ping Xu
    Pediatrics Epidemiology Center, University of South Florida, Tampa, Florida 33612, USA
    Diabetes Care 30:2314-20. 2007
    ..The purpose of this study was to determine whether insulin resistance is a risk factor for the development of type 1 diabetes in autoantibody-positive first-degree relatives of diabetic family members...
  5. pmc Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research
    Rachel L Richesson
    Pediatrics Epidemiology Center, University of South Florida College of Medicine, Department of Pediatrics, Tampa, FL 33612, USA
    J Am Med Inform Assoc 13:536-46. 2006
    ..To estimate the coverage provided by SNOMED CT for clinical research concepts represented by the items on case report forms (CRFs), as well as the semantic nature of those concepts relevant to post-coordination methods...
  6. ncbi request reprint Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes
    Jeffrey P Krischer
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612 9497, USA
    J Clin Endocrinol Metab 88:103-8. 2003
    ..Further follow-up and analysis of actual progression to diabetes will be essential to define actual diabetes risk in this large cohort...
  7. ncbi request reprint Lysophospholipids are potential biomarkers of ovarian cancer
    Rebecca Sutphen
    Department of Interdisciplinary Oncology, College of Medicine and H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, 33612, USA
    Cancer Epidemiol Biomarkers Prev 13:1185-91. 2004
    ..To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting...
  8. pmc A randomized controlled trial to increase cancer screening among attendees of community health centers
    Richard G Roetzheim
    Department of Family Medicine, University of South Florida, Tampa, Fla 33612, USA
    Ann Fam Med 2:294-300. 2004
    ..We assessed the efficacy of the Cancer Screening Office Systems (Cancer SOS), an intervention designed to increase cancer screening in primary care settings serving disadvantaged populations...
  9. ncbi request reprint Colorectal cancer screening among a sample of community health center attendees
    Lisa K Christman
    Fuller Theological Seminary, USA
    J Health Care Poor Underserved 15:281-93. 2004
    ..Our results add to a growing body of evidence that community health centers, despite serving disadvantaged populations, are able to deliver preventive care at rates comparable to health facilities used by the general population...
  10. ncbi request reprint Male sex increases the risk of autoimmunity but not type 1 diabetes
    Jeffrey P Krischer
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Diabetes Care 27:1985-90. 2004
    ..We examined both the effect of the sex of the individual screened as well as the effect of the sex of the individual's proband on diabetes risk variables tested...
  11. ncbi request reprint Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes
    Maria J Redondo
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East Ninth Avenue B 140, Denver, CO 80262, USA
    J Autoimmun 23:275-9. 2004
    ....
  12. pmc Heterogeneous but "standard" coding systems for adverse events: Issues in achieving interoperability between apples and oranges
    Rachel L Richesson
    University of South Florida College of Medicine, Tampa, FL, USA
    Contemp Clin Trials 29:635-45. 2008
    ..This paper describes the structural features of each coding system, their content and relationship to the Unified Medical Language System (UMLS), and unsettled issues for future interoperability of these standards...
  13. pmc Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan
    Yoshikazu Inoue
    Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, 754 Ichibannchoh, Asahimachi Tohri, Niigata 951 8520, Japan
    Am J Respir Crit Care Med 177:752-62. 2008
    ..Because PAP is rare, prior reports were based on limited patient numbers or a synthesis of historical data...
  14. ncbi request reprint A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 31:528-33. 2008
    ..The accurate prediction of type 1 diabetes is essential for appropriately identifying prevention trial participants. Thus, we have developed a risk score for the prediction of type 1 diabetes...
  15. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  16. ncbi request reprint TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial
    William A Hagopian
    Pacific Northwest Research Institute, Seattle, WA 98122, USA
    Ann N Y Acad Sci 1079:320-6. 2006
    ..8%) and among 910 newborns with a first-degree relative (FDR) were 194 (21%). A total of 1061 children have been enrolled. The initial enrollment results demonstrate the feasibility of this complex and demanding a prospective study...
  17. ncbi request reprint Selection of patients for clinical trials: an interactive web-based system
    Eugene Fink
    Computer Science and Engineering, University of South Florida, Tampa, FL 33620, USA
    Artif Intell Med 31:241-54. 2004
    ..The addition of a new trial takes 10-20 min, and novice users learn the functionality of the interface in about an hour...
  18. ncbi request reprint Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes
    Maria J Redondo
    Department of Endocrinology, University Clinic of Navarra, 31008 Pamplona, Spain
    J Clin Endocrinol Metab 91:1705-13. 2006
    ..Human leukocyte antigen (HLA) DQ haplotypes have the strongest genetic association with type 1 diabetes (T1DM) risk...
  19. ncbi request reprint BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
    Tuya Pal
    Division of Cancer Prevention and Control, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33617, USA
    Cancer 104:2807-16. 2005
    ..To address this gap, the authors conducted a population-based study of 232 incident epithelial ovarian carcinomas in the Tampa Bay area...
  20. ncbi request reprint Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1
    Jay S Skyler
    University of Miami, PO Box 016960 D 110, Miami, FL 33101 6960, USA
    Diabetes Care 28:1068-76. 2005
    ..This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes...
  21. ncbi request reprint Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...

Research Grants12

  1. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2003
    ..abstract_text> ..
  2. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2007
    ..abstract_text> ..
  3. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2007
    ....
  4. Trial to Reduce IDDM in the Genetically at Risk (TRIGR) Data Management Unit
    Jeffrey Krischer; Fiscal Year: 2007
    ..The data management system is a secure web based system that includes the capability to capture and integrate demographic, laboratory and clinical data. ..
  5. DATA COORDINATING CENTER
    Jeffrey Krischer; Fiscal Year: 2006
    ..This version will document all DCC procedures for data collection, transfer, quality control and data management and reporting. ..
  6. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2006
    ..abstract_text> ..
  7. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2005
    ..abstract_text> ..
  8. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2004
    ..abstract_text> ..
  9. H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE
    Jeffrey Krischer; Fiscal Year: 2005
    ....
  10. Rare Diseases Data and Technology Coordinating Center
    Jeffrey Krischer; Fiscal Year: 2004
    ..abstract_text> ..